sinc
discoveri
mediat
phenomenon
viral
interfer
ie
inhibit
growth
one
viru
anoth
interferon
ifn
becom
recogn
potent
cytokin
associ
complex
antivir
immunomodul
antiprolif
action
ifn
protein
synthes
eukaryot
cell
respons
variou
induc
caus
biochem
chang
lead
nonselect
antivir
state
expos
cell
speci
three
subfamili
ifn
recogn
type
ifn
largest
subfamili
includ
subtyp
human
type
ii
subfamili
one
member
type
iii
subfamili
recent
identifi
includ
three
subtyp
also
known
interleukin
il
fourth
interferon
subtyp
recent
identifi
type
ifn
cluster
short
arm
chromosom
human
type
ii
ifn
chromosom
type
iii
ifn
encod
chromosom
formerli
design
basi
cell
type
deriv
ifn
current
clinic
use
tabl
wherea
studi
hepat
c
type
immunolog
distinct
differ
produc
cell
induc
biolog
effect
uniqu
physicochem
characterist
produc
almost
cell
respons
viral
infect
variou
stimuli
includ
doublestrand
rna
dsrna
bacteria
protozoa
mycoplasma
polyanion
sever
lowmolecularweight
organ
compound
certain
cytokin
growth
factor
tumor
necrosi
factor
tnf
product
restrict
lymphocyt
natur
killer
cell
respond
antigen
stimuli
mitogen
certain
cytokin
also
appear
produc
multipl
cell
type
princip
antivir
ifn
approxim
homolog
aminoacid
level
human
share
high
degre
aminoacid
sequenc
homolog
differ
vitro
antivir
biolog
effect
human
cell
compar
less
antivir
activ
potent
immunoregulatori
effect
particularli
respect
macrophag
activ
express
class
ii
major
histocompat
complex
mhc
antigen
mediat
local
inflammatori
respons
ifn
clinic
use
produc
recombin
dna
techniqu
see
tabl
wide
rang
anim
virus
sensit
antivir
action
ifn
although
mani
dna
virus
rel
insensit
consider
differ
potenc
exist
among
virus
assay
system
ifn
activ
usual
measur
term
antivir
effect
cell
cultur
typic
one
unit
ifn
activ
amount
present
sampl
dilut
caus
reduct
viru
replic
express
certain
cell
line
gener
express
intern
unit
iu
rel
nation
institut
health
world
health
organ
refer
standard
ifn
directli
antivir
caus
elabor
effector
protein
expos
cell
contribut
state
viral
resist
initi
step
involv
ifn
bind
specif
cell
surfac
receptor
type
ifn
cognat
receptor
type
ii
ifn
use
homodimer
receptor
type
iii
ifn
signal
receptor
complex
consist
ifn
receptor
link
janu
kinasesign
transduc
activ
transcript
jakstat
signal
pathway
multistep
process
activ
transcript
factor
bind
select
upregul
approxim
ifnregul
gene
distinct
pattern
stat
protein
activ
differ
ifn
one
mechan
elicit
differ
cellular
respons
threeprotein
complex
interferon
potent
cytokin
stimul
antivir
immunomodul
antiprolif
effect
classifi
type
ii
iii
see
tabl
ifn
titer
gener
appear
site
viral
replic
peak
titer
viru
humor
antibodi
respons
ifn
may
mediat
system
symptom
associ
viral
infect
contribut
immunolog
mediat
tissu
damag
certain
viral
diseas
high
ifn
titer
usual
follow
reduct
viru
titer
although
persist
elev
ifn
titer
recogn
certain
chronic
acut
viral
infect
eg
hemorrhag
fever
prolong
biolog
effect
ifn
easili
relat
serum
concentr
convent
pharmacokinet
paramet
intramuscular
subcutan
inject
absorpt
greater
plasma
level
dose
relat
peak
hour
return
baselin
hour
level
synthetas
peripher
blood
mononuclear
cell
use
index
biolog
respons
ifn
show
increas
begin
hour
last
day
singl
dose
antivir
state
cell
detect
hour
peak
hour
slowli
decreas
baselin
day
inject
intramuscular
subcutan
inject
result
neglig
plasma
level
although
increas
synthetas
may
occur
oral
administr
result
detect
serum
ifn
level
increas
synthetas
activ
peripher
blood
mononuclear
cell
system
administr
low
level
ifn
detect
respiratori
secret
cerebrospin
fluid
eye
brain
intraven
dose
cerebrospin
fluid
level
averag
less
serum
concentr
stabl
bodi
fluid
wherea
seem
lose
activ
readili
unknown
howev
whether
measur
ifn
level
particular
site
accur
reflect
antivir
biolog
activ
clear
rapidli
complex
fashion
leukocyt
recombin
speci
plasma
elimin
halflif
elim
hour
clearanc
ifn
includ
inactiv
variou
bodi
fluid
cellular
uptak
metabol
bodi
organ
primarili
kidney
although
neglig
biolog
activ
ifn
excret
known
ifnstimul
gene
factor
local
nucleu
bind
cisact
dna
element
design
irs
activ
transcript
target
gene
famili
ifn
regulatori
factor
exist
pathway
may
contribut
regul
ifn
respons
microarray
analysi
show
mani
gene
upregul
vitro
onset
ifninduc
antivir
action
rapid
ifn
exposur
lead
product
two
dozen
cellular
protein
mani
virus
primari
antivir
effect
ifn
vitro
mediat
inhibit
viral
protein
synthesi
depend
viru
cell
type
antivir
action
ifn
may
also
includ
inhibit
viral
penetr
uncoat
synthesi
methyl
messeng
rna
viral
assembl
releas
among
bettercharacter
ifninduc
protein
uniqu
synthetas
protein
kinas
r
pkr
either
inhibit
protein
synthesi
presenc
dsrna
synthetas
produc
adenyl
oligom
activ
latent
cellular
endoribonucleas
rnase
l
cleav
cellular
viral
singlestrand
ss
rna
lead
inhibit
protein
synthesi
activ
pkr
select
phosphoryl
inactiv
eukaryot
initi
factor
eif
imped
translat
activ
pkr
also
phosphoryl
transcript
factor
inhibitor
mediat
dsrnainduc
activ
nuclear
factor
nf
requir
synthesi
ifn
may
also
block
mrna
cap
inhibit
transmethyl
reaction
ifn
also
induc
human
guanyl
bind
mediat
antivir
activ
sever
rna
virus
solubl
form
lowdens
lipoprotein
receptor
inhibitori
rhabdoviru
assembl
mxa
protein
guanosin
triphosphatas
activ
orthomyxovirus
certain
rna
virus
rnaspecif
adenosin
deaminas
modifi
rna
transcript
transcript
ifn
also
inhibit
hepatit
c
viru
hcv
intern
ribosom
entri
sitedepend
rna
translat
vitro
induct
nitric
oxid
synthas
seem
mediat
substanti
antivir
effect
increas
level
synthetas
activ
mxa
protein
mrna
peripher
leukocyt
also
use
marker
ifn
exposur
endogen
releas
except
possibl
mx
protein
influenza
virus
synthetasernasel
picornavirus
consist
correl
exist
induct
particular
protein
resist
specif
viru
across
rang
cell
type
particular
viru
may
inhibit
sever
step
princip
inhibitori
effect
differ
among
viru
famili
mani
virus
abl
counter
ifn
effect
block
signal
product
activ
select
ifninduc
protein
protein
hcv
repress
function
ifninduc
pkr
anoth
hepat
c
viru
protein
competit
inhibit
pkr
kinas
activ
gene
influenza
ifn
antagonist
bind
dsrna
inhibit
ifn
product
dsrnaactiv
pathway
ifn
exposur
may
also
reduc
express
certain
cellular
gene
includ
select
oncogen
gene
involv
collagen
synthesi
viral
immun
ifn
system
function
nonredund
complex
interact
exist
ifn
ifn
part
immun
system
ifn
upregul
major
antihcv
antibodi
experi
worsen
diseas
treat
ifn
advers
effect
pegifn
similar
advers
effect
convent
ifn
although
doserel
neutropenia
thrombocytopenia
inject
site
reaction
common
pegifntr
patient
chronic
hepat
c
develop
fatigu
system
symptom
inject
experi
depress
psychiatr
reaction
approxim
discontinu
treatment
advers
event
commonli
psychiatr
disord
may
associ
lesser
frequenc
depress
develop
serum
neutral
antibodi
exogen
ifn
vari
ifn
type
dosag
rout
administr
may
common
neutral
antibodi
may
associ
infrequ
loss
clinic
respons
pegyl
may
reduc
immunogen
ifn
antipeg
antibodi
seem
rare
ifn
may
impair
fertil
alter
hormon
level
women
ifn
abortifaci
monkey
high
dosag
use
small
number
pregnant
women
safeti
pregnanc
establish
classifi
pregnanc
categori
c
ifn
undergon
clinic
studi
broad
varieti
infect
malign
diseas
depend
ifn
type
recombin
natur
see
tabl
although
ifn
associ
antivir
effect
herp
simplex
virus
hsv
consist
reduct
symptom
lesion
durat
observ
topic
system
ifn
treatment
genit
herp
topic
ifn
seem
activ
combin
trifluridin
drugresist
mucocutan
hsv
infect
superfici
hsv
kerat
combin
administr
topic
trifluridin
acyclovir
seem
effect
singleag
therapi
local
herp
zoster
cancer
patient
earli
treatment
highdos
million
iuday
day
reduc
risk
cutan
viscer
dissemin
system
reaction
frequent
effect
antivir
agent
avail
ifn
ineffect
prevent
cytomegaloviru
cmv
infect
bone
marrow
recipi
treat
cmv
pneumonia
hivinfect
patient
frequent
detect
ifn
level
plasma
inhibitor
ifn
activ
often
present
acquir
immunodefici
syndrom
high
dose
induc
respons
rate
patient
kaposi
sarcoma
without
benefit
concurr
herpesviru
infect
immun
function
ifn
treatment
associ
doserel
antiretrovir
effect
particularli
earlystag
infect
also
advers
effect
ifn
seem
benefit
hivrel
thrombocytopenia
eosinophil
follicul
intralesion
system
form
administr
ifn
produc
regress
anogenit
wart
although
costeffect
better
toler
modal
avail
see
chapter
intralesion
inject
variou
natur
recombin
ifn
associ
complet
clearanc
inject
wart
patient
within
week
respond
low
relaps
rate
respons
poor
hivinfect
patient
patient
chronic
lesion
intralesion
ifn
reliabl
increas
urin
clearanc
reduc
hemodialysi
patient
attach
polyethylen
glycol
ifn
slow
absorpt
decreas
clearanc
increas
elim
result
higher
sustain
serum
concentr
onceweekli
dose
effect
two
type
pegyl
peg
current
approv
branch
polyethylen
glycol
moieti
attach
stabl
amid
bond
lysin
residu
within
ifn
protein
linear
moieti
attach
histidin
residu
stabl
dispens
solut
wherea
requir
reconstitut
use
clear
primarili
liver
wherea
clear
renal
multipl
dose
peak
serum
concentr
ngml
occur
hour
dose
elim
hour
steadyst
serum
level
attain
week
initi
weekli
dose
moder
renal
impair
presenc
cirrhosi
affect
pharmacokinet
although
clearanc
reduc
patient
renal
failur
hemodialysi
doserel
maxim
plasma
concentr
ngml
multipl
dose
occur
hour
dose
declin
elim
hour
longer
accumul
occur
repetit
dose
dosag
reduct
pegifn
indic
endstag
renal
diseas
ifn
induc
reduc
metabol
variou
drug
hepat
cytochrom
mixedfunct
oxidas
system
specif
decreas
clearanc
theophyllin
ifn
may
increas
neurotox
hematotox
cardiotox
effect
drug
includ
increas
risk
anemia
ribavirin
purifi
natur
recombin
ifn
associ
doserel
immediateand
lateonset
toxic
advers
effect
gener
mild
revers
dosag
less
million
iuday
intramuscular
subcutan
inject
ifn
dose
million
iu
usual
associ
acut
influenzalik
syndrom
includ
fever
chill
headach
malais
myalgia
arthralgia
nausea
vomit
diarrhea
especi
first
week
therapi
symptom
begin
sever
hour
administr
promin
hour
dose
despit
prolong
blood
level
durat
influenzalik
symptom
pegifn
similar
convent
ifn
toler
develop
patient
within
sever
week
febril
respons
moder
pretreat
variou
antipyret
half
patient
receiv
intralesion
therapi
genit
wart
experi
influenzalik
ill
intralesion
ifn
also
caus
discomfort
inject
site
leukopenia
local
reaction
consist
tender
erythema
also
occur
subcutan
inject
intranas
ifn
caus
local
irrit
major
toxic
limit
dosag
durat
ifn
therapi
bone
marrow
suppress
granulocytopenia
thrombocytopenia
neuropsychiatr
disturb
manifest
depress
anxieti
somnol
confus
behavior
disturb
electroencephalograph
chang
rare
seizur
revers
neurasthenia
profound
fatigu
anorexia
weight
loss
myalgia
thyroid
dysfunct
autoimmun
thyroid
cardiotox
hypotens
arrhythmia
revers
cardiomyopathi
psychiatr
disturb
depress
common
patient
preexist
disord
also
occur
otherwis
healthi
individu
elev
hepat
enzym
triglycerid
retinopathi
common
ifn
may
lead
develop
exacerb
variou
immunolog
mediat
disord
includ
sarcoidosi
system
lupu
erythematosu
psoriasi
vitiligo
lichen
planu
eczematoid
skin
lesion
rare
pulmonari
manifest
includ
interstiti
pneumonia
bronchiol
obliteran
organ
pneumonia
asthma
pleural
effus
alopecia
proteinuria
renal
insuffici
interstiti
nephriti
autoantibodi
format
bacteri
infect
hepatotox
occur
acut
allerg
reaction
rare
patient
autoimmun
chronic
hepat
may
falseposit
enzym
immunoassay
test
clearanc
averag
week
recurr
less
common
abl
therapi
retreat
frequent
success
imiquimod
may
use
adjunct
laser
surgic
abl
therapi
imiquimod
use
wart
nongenit
site
type
hpvrelat
condit
grade
grade
intraepitheli
neoplasia
vulva
respond
imiquimod
therapi
hpv
anal
infect
hivinfect
men
may
may
respond
imiquimod
seem
benefici
refractori
cutan
leishmaniasi
combin
drug
although
author
observ
benefit
combin
standard
intraven
antimoni
therapi
imiquimod
depend
level
immunocompet
imiquimod
may
benefici
treatment
molluscum
contagiosum
imiquimod
use
success
treat
chronic
genit
herp
resist
acyclovir
foscarnet
immunocompromis
individu
hiv
druginduc
immunosuppress
benefici
effect
lesion
recurr
seen
immunocompet
adult
genit
herp
imiquimod
cream
made
recurr
herp
labiali
lesion
wors
compar
vehicl
cream
control
increas
time
next
recurr
median
day
day
control
imiquimodtr
group
viral
infect
report
respond
imiquimod
includ
oral
hairi
leukoplakia
orf
kaposi
sarcoma
tinea
pedi
resolv
imiquimod
treatment
contigu
basal
cell
carcinoma
encourag
preliminari
find
topic
resiquimod
investig
treatment
recurr
genit
herp
effort
reduc
recurr
howev
control
studi
show
effect
imiquimod
rate
recurr
resiquimod
gel
appli
recurr
genit
herp
lesion
two
time
week
week
neither
reduc
heal
time
shed
herp
simplex
viru
dna
polymeras
chain
reaction
assay
compar
control
gel
treatment
regimen
associ
subsequ
day
reduct
lesion
recurr
rate
trend
toward
reduc
shed
seven
month
later
recurr
rate
reduc
control
resiquimod
group
howev
phase
iii
studi
resiquimod
show
reduc
rate
recurr
develop
drug
treat
anogenit
herp
halt
topic
applic
imiquimod
cream
affect
skin
result
system
absorpt
serum
level
ngml
patient
treat
imiquimod
need
wash
affect
area
awaken
remov
residu
drug
two
third
treat
patient
experi
local
erythema
applic
site
reaction
erythema
irrit
pruritu
burn
tender
scab
less
often
eros
ulcer
wart
site
expos
area
gener
mild
moder
intens
usual
resolv
within
week
cessat
drug
frequenc
local
reaction
relat
frequenc
applic
use
genit
herp
may
delay
heal
sever
local
reaction
includ
pain
erythema
scar
rare
unusu
local
reaction
includ
eros
cheiliti
aphthou
ulcer
angioedema
urticaria
worsen
psoriasi
system
reaction
imiquimod
fatigu
influenzalik
symptom
report
infrequ
gener
psoriasi
eczema
exacerb
myasthenia
gravi
worsen
spondyloarthropathi
report
topic
therapi
imiquimod
system
reaction
may
caus
drug
rather
diffus
cytokin
skin
system
circul
repeat
applic
small
concentr
ngml
imiquimod
detect
blood
safeti
pregnanc
establish
pregnanc
categori
b
case
report
safe
use
pregnant
women
preclin
studi
indic
imiquimod
genotox
teratogen
fig
pleconaril
inhibit
picornaviru
replic
bind
specif
hydrophob
pocket
within
viral
capsid
prevent
viral
attach
uncoat
genom
cell
respons
local
therapi
mild
moder
system
side
effect
dropout
rate
pain
irrit
inject
site
leukopenia
common
intralesion
ifn
topic
ifn
gel
provid
inconsist
effect
seem
reduc
recurr
rate
substanti
abl
therapi
system
ifn
may
provid
adjunct
benefit
recurr
juvenil
laryng
papillomatosi
children
initi
decreas
lesion
recurr
rate
high
cessat
therapi
longterm
respons
parenter
variabl
laryng
diseas
older
patient
seem
respons
except
adenoviru
ifn
broadspectrum
antivir
activ
respiratori
virus
vitro
includ
sever
acut
respiratori
syndrom
sar
coronaviru
experiment
induc
infect
human
intranas
administr
leukocyt
recombin
protect
rhinoviru
coronaviru
respiratori
syncyti
viru
rsv
lesser
extent
influenza
viru
infect
natur
condit
prophylact
intranas
protect
rhinoviru
cold
howev
longterm
use
limit
occurr
nasal
side
effect
intranas
ineffect
treat
rhinoviru
cold
inhibit
sar
coronaviru
replic
vitro
system
use
treat
sar
coronaviru
ill
benefici
effect
unclear
imiquimod
resiquimod
imiquimod
aldara
imidazoquinolin
compound
fig
agonist
act
topic
immun
respons
modifi
lack
direct
antivir
effect
imiquimod
exposur
caus
activ
immun
cell
monocyt
macrophag
natur
killer
cell
produc
antivir
cytokin
particularli
interleukin
il
imiquimod
indirectli
enhanc
acquir
immun
respons
activ
antigenpres
dendrit
cell
includ
langerhan
cell
lymphocyt
product
cell
stimul
cytotox
lymphocyt
import
clearanc
viral
infect
cell
clinic
respons
anogenit
wart
associ
decreas
human
papillomaviru
hpv
dna
copi
rna
transcript
treat
skin
resiquimod
structur
relat
investig
compound
see
fig
agonist
associ
greater
stimul
cytokin
activ
dendrit
cell
topic
imiquimod
cream
approv
patientappli
treatment
anogenit
wart
use
mucocutan
infect
dermatolog
condit
immunocompet
patient
imiquimod
three
overnight
applic
approxim
hour
weekli
week
lead
complet
wart
clearanc
clearanc
rate
differ
week
treatment
daili
applic
increas
local
advers
effect
without
increas
clearanc
rate
imiquimod
podophyllin
similar
efficaci
clearanc
rate
clearanc
rate
higher
women
men
substanti
lower
hivinfect
individu
one
studi
women
clinic
outcom
relat
hpv
type
complet
respons
rate
coinfect
hpv
type
time
oh
prolong
termin
elim
approxim
hour
singl
oral
dose
mgkg
children
provid
maxim
plasma
concentr
approxim
lower
overal
drug
exposur
larger
volum
distribut
rapid
clearanc
neonat
seem
requir
higher
dosag
part
lower
bioavail
pleconaril
gener
well
toler
common
advers
event
headach
nausea
diarrhea
abdomin
discomfort
pleconaril
induc
isoenzym
howev
consequ
potenti
multipl
drug
interact
includ
oral
contracept
children
adult
enterovir
mening
pleconaril
inconsist
effect
headach
ill
durat
pleconaril
mg
three
time
day
day
reduc
durat
uncompl
rhinoviru
cold
day
approv
us
food
drug
administr
indic
pleconaril
antivir
effect
clinic
outcom
relat
vitro
suscept
pleconaril
treatment
mgkgday
children
mgday
adult
divid
dose
day
seem
benefici
patient
sever
lifethreaten
enterovir
syndrom
includ
chronic
enterovir
meningoenceph
agammaglobulinem
patient
possibl
neonat
enterovir
sepsi
drug
formerli
avail
compassion
use
longer
cultur
pleconaril
inhibit
replic
almost
commonli
isol
enteroviru
serotyp
approxim
rhinoviru
clinic
isol
pleconaril
activ
murin
human
model
coxsackieviru
infect
adult
oral
bioavail
fed
state
peak
plasma
concentr
averag
dose
mg
pleconaril
undergo
hepat
metabol
less
excret
unchang
urin
initi
plasma
elim
averag
hour
